These (L1 cell adhesion molecule or CD171) CD171-specific CAR T-cells target the CD171-antigen overexpressed on NB cells, and are currently being investigated under phase 1 trial (NCT02311621) for the treatment of recurrent/refractory NBs (88). The gene discussed is L1CAM; the disease is Nijmegen breakage syndrome.